<DOC>
	<DOCNO>NCT00058747</DOCNO>
	<brief_summary>This Phase II , exploratory , open-label study investigational product AG-858 , patient cytogenetically positive treatment Gleevec . The trial consist three independent Phase II evaluation patient group accord cytogenetic status define eligibility criterion ( Eligibility Criteria 4a , 4b , 4c ) .</brief_summary>
	<brief_title>AG-858 Patients Who Are Cytogenetically Positive After Treatment With Gleevec™</brief_title>
	<detailed_description>The goal study determine following : - To estimate proportion patient complete cytogenetic response ( CCR ) within patient group - To estimate proportion patient substantial molecular response ( SMR ) within patient group - To evaluate frequency severity adverse event . - To assess feasibility AG-858 production .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Must Philadelphia chromosome positive chronic myelogenous leukemia first chronic phase Must complete hematologic response Must receive Gleevec™ , IFNα , cytarabine , busulfan , hydroxyurea , Homoharringtonine ( HHT ) combination thereof long combination discontinue dose Gleevec™ stable 6 month great Must one follow cytogenetic status : ( A ) Less CCR receive Gleevec™ least one year minimum dose 400 mg/day . A stable dose Gleevec™ must maintain last six month prior eligibility testing OR ( B ) Stable cytogenetic status without CCR ( cytogenic response progression ) three consecutive determination six month stable dose Gleevec™ ( minimum 400mg/day ) least 6 month OR ( C ) Cytogenetic progression stable dose Gleevec™ ( minimum dose 400mg/day ) least 2 consecutive evaluation least one month apart ECOG performance score 0 1 Must least 18 year old Not pregnant breastfeed agree use contraception course study No prior allogeneic bone marrow transplant candidate curative BMT No immunodeficiency serious illness No current use immunosuppressive medication No cancer within last five year , exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Granulocytic Leukemia , Chronic</keyword>
	<keyword>Leukemia , Granulocytic , Chronic</keyword>
	<keyword>Leukemia , Myelocytic , Chronic</keyword>
	<keyword>Leukemia , Myelogenous , Chronic</keyword>
	<keyword>Myelocytic Leukemia , Chronic</keyword>
	<keyword>Myelogenous Leukemia , Chronic</keyword>
	<keyword>Myeloid Leukemia , Chronic</keyword>
</DOC>